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A B S T R A C T
Histocompatibility testing for stem cell and solid organ transplantation has become increasingly com-
plex as newly discovered human leukocyte antigen (HLA) alleles are described. HLA typing assignments
reported by laboratories are used by physicians and donor registries for matching donors and recipients.
To communicate effectively, a common language for histocompatibility terms should be established. In
early 2010, representatives from clinical, registry, and histocompatibility organizations joined together
as the Harmonization of Histocompatibility Typing Terms Working Group to deﬁne a consensual
language for laboratories, physicians and registries to communicate histocompatibility typing informa-
tion. The Working Group deﬁned terms for HLA typing resolution, HLA matching and a format for
reporting HLA assignments. In addition, deﬁnitions of veriﬁcation typing and extended typing were
addressed. The original draft of the Deﬁnitions of Histocompatibility Typing Terms was disseminated to
colleagues from each organization to gain feedback and create a collaborative document. Commentary
gathered during this 90-day review period were discussed and implemented for preparation of this
report. Histocompatibility testing continues to evolve thus, the deﬁnitions agreed upon today, likely will
require reﬁnement and perhaps additional terminology in the future.
 2011 Published by Elsevier Inc. on behalf of American Society for Histocompatibility and
Immunogenetics.
 2011 American Society of Hematology and American society for Histocompatibility and
Open access under CC BY-NC-ND license.Immunogenetics. Open access under CC BY-NC-ND license.Deﬁnitions of histocompatibility typing terms
The deﬁnitions below are intended as general concepts. There
will be exceptions to these general deﬁnitions. These deﬁnitions do
not imply any speciﬁc requirements for human leukocyte antigen
(HLA) typing, but are meant only to deﬁne useful terms.
* Corresponding author.
E-mail address: Dawn.Wagenknecht@franciscanalliance.org (D.R. Wagen-
necht).
2011 American Society of Hematology and American society for Histocompatibil-
ty and Immunogenetics. All rights reserved. No part of this document may be
eproduced or transmitted in any form or by any means, electronic or mechanical,
ncluding photocopy, recording, or any information storage and retrieval system,
ithoutwrittenpermission by theAmerican Society ofHematology or theAmerican
ociety for Histocompatibility and Immunogenetics.
0198-8859  2011 Published by Elsevier Inc. on behalf of American Society for Histocom
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Histocompatibility testing for stem cell and solid organ trans-
plantation has become increasingly complex as newly discov-
ered human leukocyte antigen (HLA) alleles are described. HLA
typing assignments reported by laboratories are used by physi-
cians and donor registries for matching donors and recipients. To
communicate effectively, a common language for histocompati-
bility terms should be established. In early 2010, representatives
from clinical, registry, and histocompatibility organizations
joined together as the Harmonization of Histocompatibility Typ-
ing Terms Working Group to deﬁne a consensual language for
laboratories, physicians and registries to communicate histo-
compatibility typing information. The Working Group deﬁned
terms for HLA typing resolution, HLA matching and a format for
patibility and Immunogenetics. Open access under CC BY-NC-ND license.
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tion typing and extended typing were addressed. The original
draft of the Deﬁnitions of Histocompatibility Typing Terms was
disseminated to colleagues from each organization to gain feed-
back and create a collaborative document. Commentary gath-
ered during this 90-day review period were discussed and im-
plemented for preparation of this report. Histocompatibility
testing continues to evolve thus, the deﬁnitions agreed upon
today, likely will require reﬁnement and perhaps additional
terminology in the future.
2. Deﬁnitions of typing resolution
HLA laboratories should have a written agreement with each
entity requesting HLA typing for transplantation regarding the
speciﬁcations for the resolution of typing. The following terms
might be used in the agreement. These deﬁnitions do not imply
any speciﬁc requirements for typing; that decision is made by
the HLA typing laboratory in compliance with testing standards
and requirements of the test requesting entity.
2.1. Allelic resolution
The DNA-based typing result is consistent with a single allele as
deﬁned in a given version of theWorld Health Organization (WHO)
HLA Nomenclature Report as described on the reference Web site
(http://hla.alleles.org) [1]. An allele is deﬁned as a unique nucleo-
tide sequence for a gene as deﬁned by the use of all of the digits in
a current allele name. Examples include A*01:01:01:01 and
A*02:07 (designations basedon the international ImMunoGeneTics
[IMGT]/HLA Database version 3.1.0, July 2010) [2].
2.2. High resolution
A high resolution typing result is deﬁned as a set of alleles that
encode the same protein sequence for the region of the HLA mole-
cule called the antigen binding site and that excludes alleles that
are not expressed as cell-surface proteins. The antigen binding site
includes domain 1 and domain 2 of the class I  polypeptides, and
domain 1 of the class II  and domain 1 of the class II  polypeptide
chains.
2.3. Low resolution
A DNA-based typing result at the level of the digits comprising
the ﬁrst ﬁeld in the DNA-based nomenclature. Examples include
A*01; A*02. If the resolution corresponds to a serologic equivalent,
this typing result should also be called low resolution.
2.4. Other levels of resolution
If high resolution cannot be obtained, or if the laboratory’s
agreement with the entity requesting the testing limits the typing
efforts to a subset of alleles, the laboratory may report its results at
a level of resolution that falls between high resolution and low
resolution. Examples are to consider only those alleles that are
expected to be found in the local population or that are designated
as common and well deﬁned [3]. A third example is typing that
assigns a G group designation (e.g., A*02:01:01G).
3. Replacement of the term “conﬁrmatory typing”
Activities encompassed within the term “conﬁrmatory typing”
havebecomeunclear as typingpractices andmatching criteria have
changed over time. It is recommended that the following two terms
be used in the place of the words “conﬁrmatory typing” for better
clarity. “Veriﬁcation typing” and “extended typing” as deﬁned be-
low describe two distinct activities that may be performed sepa-
rately or concurrently.3.1. Veriﬁcation typing
HLA typing performed on an independent sample (or, for a cord
blood unit, from an attached segment or from the unit itself) with
the purpose of verifying concordance of that typing assignment
with the initial HLA typing assignment. Concordance does not re-
quire identical levels of resolution for the two sets of typing but
requires the two assignments to be consistent with one another.
3.2. Extended typing
HLA typing performed to add additional information to an ex-
isting HLA assignment. This additional HLA typingmay do either or
both of the following: (1) include assignments at additional HLA
loci (e.g., to type HLA-C for an HLA-A, -B, -DRB1 typed volunteer
donor), or (2) include increased resolution at any previously typed
HLA locus, e.g., to type an individual with HLA-B serologic assign-
ments to identify the HLA-B alleles. For some cases, extended typ-
ing will fulﬁll requirements for veriﬁcation typing at a particular
locus. In these cases, a combined term “veriﬁcation/extended typ-
ing” might be used.
4. Format for reporting HLA assignments
HLA typing assignments must be clearly understood by the end
user. HLA laboratories should have a written agreement with each
transplantation entity requesting HLA typing regarding the speci-
ﬁcations for the typing. The agreement can include the loci to be
tested, the level of resolution of the typing, and the format inwhich
typing results will be reported. The typing assignments must con-
form with World Health Organization nomenclature for factors of
the HLA system (http://hla.alleles.org) [1] and must comply with
other applicable international conventions (e.g., multiple allele
code deﬁnitions as designated by the National Marrow Donor Pro-
gram, as described in Bochtler et al. [4]). It might also include the
transplant center’s matching requirements if the end user requests
that the laboratory evaluate the extent of matching.
4.1. Unresolved alternative assignments
It is strongly recommended that the report to the end user
include all uncertainty in the typing assignment relevant to the
level of resolution as stated in the written agreement. This
means that genotypes and/or alleles that have not been excluded
should be listed in the report. If it is not possible to provide a list
of all unresolved alternatives on the report, the laboratory
should indicate that alternative assignments exist and provide a
rationale for the HLA assignment that is selected for inclusion in
the report. The impact of any uncertainty in HLA assignments for
either the potential donor or patient on matching should be
addressed in the report.
4.2. Database used in interpretation of typing results
The version of the IMGT/HLADatabase used to interpret theHLA
results should be available to the end user upon request.
4.3. Reporting a string of alleles
Slashes should be used to separate a string of alternative alleles,
e.g., A*02:01/02:02/02:07/02:20 to mean A*02:01 or A*02:02 or
A*02:07 or A*02:20. Based upon resolution requirements, allele
names might be truncated from the right; for example A*02:01 is
understood to include all silent substitutions, differences outside
the coding region and expression codes that begin with the digits
02:01. Left truncation leads to confusion of the allele family and
allele number and thus should not be used.
5. Matching
When providing HLA assignments for a potential donor and
patient for allogeneic transplantation, the laboratory should in-
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local, national, or international standards.
5.1. Directionality of match
The laboratory may wish to refer to directionality (or vector) of
the mismatch in cases in which the patient or a potential donor is
homozygous at a locus or has a nonexpressed allele. If the patient is
homozygous and one of the HLA assignments is identical to an
assignment of the heterozygous donor (e.g., patient A*01:01:01:01,
potential donor A*01:01:01:01, A*23:01), the mismatch may be
referred to as amismatch in the host versus graft vector direction. If
he potential donor is homozygous and one of theHLA assignments
s identical to an assignment of the heterozygous patient, the mis-
atch may be referred to as a mismatch in the graft versus host
ector direction.
.2. Matching within a family
.2.1. HLA haplotypes identical by descent
This phrasemay be usedwhen (1) parental HLA assignments are
vailable, (2) all four haplotypes are unequivocally deﬁned in the
amily, (3) the HLA assignments of the parents are clearly distin-
uishable from one another, and (4) the assignments include HLA
lass I and class II loci to the extent that potential recombinations
ave been ruled out. The patient and potential donor who share
oth haplotypes may be described as HLA identical by descent.
.2.2. HLA identical for all loci tested
This phrase may be used to refer to matching of related donors
ho appear to share the HLA loci tested with the patient based on
egregationwithin the family. This phrase would refer tomatching
n which not all HLA loci are tested (e.g., HLA-A, -B, -C, DRB1 typed
ut not DQB1 or DPB1) so the possibility of recombination is not
xcluded.
.2.3. Families in which segregation to conﬁrm identity by descent is
ot possible
When it is not possible to unequivocally deﬁne haplotypes, the
hrases used to describe matching should be those used for an
nrelated donor as described below.
.3. Matching of patient to unrelated donor or matching within a
amily where identity by descent cannot be ascertained
.3.1. Matched for {insert} at {insert} resolution
Aphrase like thismightbeusedtorefer to thenumberof loci tested
i.e., two assignments at three loci yielding six assignments to include
LA-A, -B, -DRB1, or four loci yielding eight assignments with theddition of HLA-C or 10 assignments with the addition of HLA-DQB1
r 12 assignments with DPB1), the potential identity of the assign-
ents (e.g., eight of eight or seven of eight or nine of 10), and the level
f resolution used to determine the potential identity (e.g., high reso-
ution or low resolution). The number of loci to be included in this
rading of match should be agreed locally with the service users.
For example, an umbilical cord blood unit may be described as
matched for six of six at low resolution forHLA-A andHLA-B and at
llelic level resolution for HLA-DRB1” with the patient. For exam-
le, an adult volunteer donor may be described as “matched for
ine of 10 at high resolution” with the patient.
. Reference Web site
Information on the current status of this document can be found
t http://hla.alleles.org.
. Approval
These deﬁnitions have been reviewed by representatives from
he organizations listed below. The extent to which each organiza-
ion is able to incorporate the deﬁnitions above can be found on the
eb site for each organization.
ABB
merican Society for Blood and Marrow Transplantation (ASBMT)
merican Society for Histocompatibility and Immunogenetics
ASHI)
ollege of American Pathologists (CAP)
uropean Federation for Immunogenetics (EFI)
oundation for the Accreditation of Cellular Therapy (FACT)
ational Marrow Donor Program (NMDP)
orld Marrow Donor Association (WMDA)
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